Dipeptide bioregulator (ED) of glutamic acid and aspartic acid, from the Khavinson series, developed at the St. Petersburg Institute of Bioregulation and Gerontology. Function of the urinary tract and bladder is what it is designed to support, and research indicates potential benefit to prostate health in men. Proposed effects are smooth muscle regulation, better blood flow through tissue, and cellular regeneration in urogenital tissues. It is a distinct compound from Vesugen, the KED tripeptide, whose target is vascular endothelium.